Allogeneic Umbilical Cord Blood Therapy in Children With CP

This study is currently recruiting participants. (see Contacts and Locations)
Verified July 2014 by Bundang CHA Hospital
Sponsor:
Collaborator:
CHA University
Information provided by (Responsible Party):
MinYoung Kim, M.D., Bundang CHA Hospital
ClinicalTrials.gov Identifier:
NCT02025972
First received: December 29, 2013
Last updated: July 18, 2014
Last verified: July 2014

December 29, 2013
July 18, 2014
December 2013
December 2015   (final data collection date for primary outcome measure)
  • Cytokine analysis [ Time Frame: 12 months ] [ Designated as safety issue: No ]
    Cytokine analysis
  • Changes in Standardized Gross Motor Function [ Time Frame: Baseline - 3 months - 6 months - 12months ] [ Designated as safety issue: No ]
    GMFM (Gross Motor Function Measure) is a standardized measurement tool for assessing gross motor function consisting of sub-scales; lying & rolling, sitting, crawling & kneeling, standing, walking, running & jumping (range: 0~100, higher value means better gross motor function).
  • Changes in Motor Performance [ Time Frame: Baseline - 3 months - 6 months - 12 months ] [ Designated as safety issue: No ]
    GMPM (Gross Motor Performance Measure) is a standardized measurement tool for assessing quality of movement regarding 3 properties of 5 ones; alignment, coordination, dissociated movement, stability, and weight shift (range: 0~100, higher value means better motor quality).
  • Changes in Cognitive Neurodevelopmental Outcome [ Time Frame: Baseline - 3 months - 6 months - 12 months ] [ Designated as safety issue: No ]
    Korean version of Bayley Scale of Infant Development-II (K-BSID-II) Mental Scale (range: 0~178; worst: 0, best: 178)
  • Changes in Motor Neurodevelopmental Outcome [ Time Frame: Baseline - 3 months - 6 months - 12 months ] [ Designated as safety issue: No ]
    Korean version of Bayley Scale of Infant Development-II (K-BSID-II) Motor Scale (range: 0~112; worst: 0, best: 112)
Same as current
Complete list of historical versions of study NCT02025972 on ClinicalTrials.gov Archive Site
  • Changes in Gross Motor Function Classification System [ Time Frame: Baseline - 3 months - 6 months - 12 months ] [ Designated as safety issue: No ]
    GMFCS (Gross Motor Function Classification System) is a five-level classification system based on self-initiated movement, with emphasis on sitting, transfers, and mobility (level I: walks without limitations, ll: walks with limitations, III: walks using a hand-held mobility device, IV: self-mobility with limitations, V: transported in a manual wheelchair).
  • Changes in Functional Independence in Daily Activities [ Time Frame: Baseline - 3 months - 6 months - 12 months ] [ Designated as safety issue: No ]
    WeeFIM (Functional Independence Measure for Children) measures functional independence in daily activities. WeeFIM contains 18 items and each item is ranked from complete dependence (scored as 1) to complete independence (scored as 7). The range is from 18 to 126 and higher score means more independent performance in daily activities.
  • Changes in Functional Performance in Daily Activities [ Time Frame: Baseline - 3 months - 6 months - 12 months ] [ Designated as safety issue: No ]
    Pediatric Evaluation of Disability Inventory (PEDI) is used to assess functional performance in daily activities in children (All values are adjusted and higher value means better functional performance, 0 - worst, 100 - best). PEDI consists of 2 scales such as Functional Skill Scale (FSS) and a Caregiver Assistance Scale (CAS) and each scale is composed of 3 domains including self care, mobility, and social function.
  • Changes in Upper Extremity Function [ Time Frame: Baseline - 3 months - 6 months - 12 months ] [ Designated as safety issue: No ]
    QUEST (Quality of Upper Extremity Skills Test) is a standardized measurement tool for assessing upper extremity function consisting of sub-scales; dissociated movement, grasps, weight bearing, and protective extension. QUEST ranges from 0 (or below 0 in grasp section) to 100 and higher values mean better upper extremity function.
  • Changes in Visual Perception Test [ Time Frame: Baseline - 3 months - 6 months - 12 months ] [ Designated as safety issue: No ]
    Visual perception function will be assessed with one of 3 tools such as DTVP (Developmental Test of Visual Perception), MVPT (Motor-free Visual Perception Test), and VMI (Visual-Motor Integration, Visual Perception and Motor Coordination). Higher value means better visual perception ability.
  • Changes in Selective Movement of Lower Extremity [ Time Frame: Baseline - 3 months - 6 months - 12 months ] [ Designated as safety issue: No ]
    SCALE (Selective Control Assessment of Lower Extremity) is a measurement tool of selective movement of hip, knee, ankle, subtalar joint and toes. Selective voluntary motor control is graded at each joint as normal (2 points), impaired (1 point) or unable (0 point).
  • Changes in Spasticity [ Time Frame: Baseline - 3 months - 6 months - 12 months ] [ Designated as safety issue: No ]
    Muscle spasticity of biceps, hip adductors, hamstrings and heel cords is graded according to modified Ashworth scale (MAS).
  • Changes in Dynamic Component of Spasticity [ Time Frame: Baseline - 3 months - 6 months - 12 months ] [ Designated as safety issue: No ]
    Dynamic component of spasticity in bilateral hamstrings is graded using modified Tardieu scale (MTS).
  • Changes in Muscle Strength [ Time Frame: Baseline - 3 months - 6 months - 12 months ] [ Designated as safety issue: No ]
    Muscle strength is measured using summated scores of manual muscle test (zero=0, trace=1, poor=2, fair=3, good=4, normal=5) for flexors, extensors, abductors, and adductors of bilateral shoulder and hip joints; flexors and extensors of bilateral elbow, wrist, and knee; dorsiflexors and plantar flexors of the ankles (range: 0 ~ 160). Higher score means stronger muscle power.
  • Changes in Brain MRI [ Time Frame: Baseline - 12 months ] [ Designated as safety issue: No ]
    Diffusion Tensor Image (DTI) of brain MRI (magnetic resonance imaging) provides quantitative information about the microscopic integrity of white matter. White matter normally possesses a high degree of diffusion anisotropy than gray matter. Fractional anisotropy (FA) will be measured and it ranges from 0 to 1. Higher FA value means more integrity of white matter.
  • Changes in Brain 18F-FDG PET [ Time Frame: Baseline - 12 months ] [ Designated as safety issue: No ]
    18F-FDG PET (Positron emission tomography with fluorine-18-fluorodeoxyglucose) imaging will be performed twice prior to and 12 months after UCB therapy.
  • Changes in EEG [ Time Frame: Baseline - 12 months ] [ Designated as safety issue: No ]
    Electroencephalography (EEG) will be performed twice prior to and 12 months after UCB therapy.
  • Changes in EP [ Time Frame: Baseline - 12 months ] [ Designated as safety issue: No ]
    Median, tibial somatosensory evoked potential (SEP), visual evoked potential (VEP), auditory evoked potential (AEP) will be performed twice prior to and 12 months after UCB therapy.
  • Number of adverse events and participants with those adverse events [ Time Frame: 12 months ] [ Designated as safety issue: Yes ]
    The numbers of adverse events and subjects with those serious adverse events within each group; A serious adverse event is any untoward medical occurrence that at any dose: results in death or is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, or causes a congenital anomaly/birth defect.
Same as current
Not Provided
Not Provided
 
Allogeneic Umbilical Cord Blood Therapy in Children With CP
Changes in Cytokines and Functional Outcomes of Allogeneic Cord Blood Therapy in Children With Cerebral Palsy

This open-label study aims to analyze cytokines related to clinical outcomes of allogeneic umbilical cord blood therapy for children with cerebral palsy.

Cerebral palsy (CP) is a group of neurodevelopmental conditions with abnormal movement and posture resulted from a non-progressive cerebral disturbance. It is the most common cause of motor disability in childhood. Most therapies are palliative rather than restorative. Umbilical cord blood (UCB) may be used as restorative approach for children with CP.

Many experimental animal studies have revealed that UCB is beneficial to improve and repair neurological injuries.

Based on animal studies and some clinical trials, UCB is suggested as a potential therapy for children with CP. This study was designed to find cytokines relevant to UCB therapy.

Interventional
Not Provided
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Cerebral Palsy
Procedure: Allogeneic umbilical cord blood therapy
Experimental: Allogeneic umbilical cord blood therapy
Allogeneic umbilical cord blood therapy
Intervention: Procedure: Allogeneic umbilical cord blood therapy
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
18
December 2015
December 2015   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Diagnosed with cerebral palsy
  • Age of ≤15 years
  • Mismatch in HLA-A, B, and DR ≤2, and total nucleated cell count ≥3x10^7/kg. If the cell count is less than given values, more than 1 unit could be used.
  • Decision of participation in the study by and acquisition of informed consent from the subject's representative
  • Willingness and ability to be hospitalized according to the schedule specified in the protocol and continue the study for 12 months after study entry

Exclusion Criteria:

  • Current aspiration pneumonia
  • Known genetic disease
  • History of hypersensitivity reaction to any study drugs pertinent to the study
  • Patient with severe seizure disease who has clinical convulsion despite combination therapy with 3 or more agents
  • Uncontrolled hypertension defined as systolic blood pressure >115 mmHg and/or diastolic blood pressure >70 mmHg
  • Hepatic impairment defined as asparate aminotransferase (AST) >55 IU/L and/or alanine aminotransferase (ALT) >45 IU/L
  • Renal impairment defined as creatinine (Cr) ≥1.2 mg/dL
  • Presence of diagnosed or suspected malignant tumor and/or hematologic malignancy
  • Non-compliance with study visits specified in the protocol or unwillingness of care-giver due to lack of understanding of the patient
Both
up to 15 Years
No
Contact: MinYoung Kim, M.D., Ph.D. 82-31-780-6281 kmin@cha.ac.kr
Contact: Kyunghoon Min, M.D. 82-31-780-6281 minkh@chamc.co.kr
Korea, Republic of
 
NCT02025972
UCBCP
No
MinYoung Kim, M.D., Bundang CHA Hospital
MinYoung Kim, M.D.
CHA University
Principal Investigator: MinYoung Kim, M.D., Ph.D. CHA University
Bundang CHA Hospital
July 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP